- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02536534
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension (e-MOTION PH)
19. december 2017 opdateret af: Bayer
(e-MOTION PH) Electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) over 6 months in routine clinical practice settings.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Remote patient monitoring can lead to improved patient outcomes, including improved quality of life, reduced readmissions, earlier treatment for symptoms detected prior to schedule in-office follow-up visits, improved communications with care providers, increased participation in self-management of disease, and an improved knowledge of their medical conditions .
In patients with PAH, daily activity level, as measured using a physical activity monitor for seven consecutive days, correlated with 6-minute walk distance (6MWD).
The monitor used in the aforementioned PAH study was positioned on the patients' right upper arm with an armband, as opposed to the more popular and more comfortable wristbands used today, such as the Fitbit Flex.
Although the aforementioned PAH study did show a correlation between activity level monitoring and 6MWD, the patients were monitored for only seven days.
It is still unknown whether this correlation would exist over a longer trial period and whether patients, their caregivers, and clinicians would find activity level monitoring useful in helping manage PH.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
35
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Multiple Locations, Canada
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Canadian patients are eligible for the study if they have been diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and are stable on optimal medical therapy and who meet the study's eligibility criteria
Beskrivelse
Inclusion Criteria:
- Male or female patients with a diagnosis of Pulmonary Arterial Hypertension (PAH); or inoperable, persistent or recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH),
- Age ≥ 18 years,
- Baseline 6 Minute Walk Distance (6MWD) a minimum of 250 meters or maximum 450 meters, (ensure significant Pulmonary Hypertension(PH) without limiting their participation in the trial)
- WHO Functional Class II or III,
Clinically stable patient defined as within the last 12 months (minimum of 3 months) prior to enrollment, there was no:
- decline in World Health Organization (WHO) Function class or,
- decline in 6MWD by 15% or,
- change of oral PAH/CTEPH therapy (may have flexible diuretics/anticoagulation) or,
- Introduction of parenteral Prostacyclin Analog (PCA) treatment.
- Patients provide written informed consent, are able to understand and follow instructions.
Exclusion Criteria:
- Hypersensitivity to nickel (present in the clasp of the FitBit Flex's band),
- Medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator,
- Enrolled in pulmonary rehabilitation program within last 6 months,
- Participating in an interventional study.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Patients with PAH and CTEPH
Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
6-minute walk distance (6MWD)
Tidsramme: At baseline
|
(performed by investigator)
|
At baseline
|
|
6-minute walk distance (6MWD)
Tidsramme: At 3 months
|
(performed by investigator)
|
At 3 months
|
|
6-minute walk distance (6MWD)
Tidsramme: At 6 months
|
(performed by investigator)
|
At 6 months
|
|
Number of steps per day
Tidsramme: At baseline
|
(monitored by Fitbit Flex)
|
At baseline
|
|
Number of steps per day
Tidsramme: At 3 months
|
(monitored by Fitbit Flex)
|
At 3 months
|
|
Number of steps per day
Tidsramme: At 6 months
|
(monitored by Fitbit Flex)
|
At 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in quality of life recorded by patient questionnaire Living with Pulmonary hypertension Questionnaire (LPH)
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Change in compliance with medication using the Moriky´s Questionnaire
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Change in World Health Organization (WHO) functional Class recorded by investigator in conjunction with the 6MWD
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Change in Borg Dyspnea value recorded by investigator in conjunction with the 6MWD
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Healthcare provider Satisfaction and Usability questionnaire
Tidsramme: At 3 months and 6 months
|
At 3 months and 6 months
|
|
Caregiver Satisfaction and Usability questionnaire
Tidsramme: At 3 months and 6 months
|
At 3 months and 6 months
|
|
Patient Satisfaction and Usability questionnaire
Tidsramme: At 3 months and 6 months
|
At 3 months and 6 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
30. juni 2015
Primær færdiggørelse (Faktiske)
25. november 2016
Studieafslutning (Faktiske)
21. december 2016
Datoer for studieregistrering
Først indsendt
10. august 2015
Først indsendt, der opfyldte QC-kriterier
31. august 2015
Først opslået (Skøn)
1. september 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
20. december 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
19. december 2017
Sidst verificeret
1. december 2017
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 17926
- DBOX 2014/00466 (Anden identifikator: Company internal)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hypertension, lunge
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Inhibikase TherapeuticsIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Rutgers, The State University of New JerseyRekrutteringPulmonal arteriel hypertension | Pulmonal hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension af medfødt hjertesygdom | Pulmonal arteriel hypertension forbundet med skistosomiasis (lidelse) | Pulmonal arteriel og kronisk tromboembolisk pulmonal... og andre forholdForenede Stater
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
-
University Hospital, BrestIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Frankrig
Kliniske forsøg med Correlation assessment
-
Al-Azhar UniversityRekrutteringCaries i tænderne | Udbrud | BMIEgypten
-
Empatica, Inc.United States Department of DefenseAfsluttet
-
Thomas Jefferson UniversityAfsluttetHæmatopoietisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForenede Stater
-
Guy's and St Thomas' NHS Foundation TrustMacusoftIkke rekrutterer endnuDiabetisk makulært ødem | Retinal veneokklusion | Våd makuladegenerationDet Forenede Kongerige
-
University Hospital, LilleAfsluttetKognitivt symptom | Evalueringer, Diagnostisk SelvFrankrig
-
Texas Woman's UniversityAfsluttetAutismespektrumforstyrrelse
-
Alzheimer's Light LLCRekrutteringMultipel sclerose | Parkinsons sygdom | Alzheimers sygdom | Mild kognitiv svækkelse | Frontotemporal demens | Vaskulær demens | TBIForenede Stater
-
University of OklahomaTrukket tilbageLivmoderhalskræft | Hoved- og halskræft | Gynækologisk kræft | EndometriecancerForenede Stater
-
Natera, Inc.Trukket tilbageHjertetransplantationssvigt og afvisning
-
Mansoura University HospitalAfsluttetIskæmisk slagtilfælde | Kognitiv svækkelse | Udfald, fataltEgypten